Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.50 |
| ▸ | JAK2 | O60674 | 11/20 | 0.48 |
| ▸ | TYK2 | P29597 | 9/20 | 0.48 |
| ▸ | JAK3 | P52333 | 9/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724518 | 0.87 | JAK1 (0.53) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL21724451 | 0.85 | TLR7 (0.42) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL23910159 | 0.84 | JAK1 (0.40) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL30777927 | 0.84 | JAK1 (0.40) | JAK1JAK2TYK2JAK3OPRM1 | |
| SCHEMBL1233687 | 0.78 | DYRK1A (0.40) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL28580870 | 0.78 | JAK1 (0.35) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL1233021 | 0.77 | DYRK1A (0.45) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL4758727 | 0.76 | EGFR (0.38) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL22336631 | 0.74 | TLR7 (0.40) | — | |
| SCHEMBL23037677 | 0.73 | NQO2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024513-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3837015-B1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20210317118-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3837015-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112996567-A | Imidazo [4,5-C ] quinoline-derived NLRP 3-modulators | 先天肿瘤免疫公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037092-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024513-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | JAK1 2951/4885JAK2 3101/4885TYK2 2810/4885 |
| US-20210317118-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | JAK1 2951/4885JAK2 3101/4885TYK2 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.